VolitionRXVNRX
About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Employees: 85
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
7% more capital invested
Capital invested by funds: $11.2M [Q4 2024] → $12M (+$762K) [Q1 2025]
2.42% more ownership
Funds ownership: 19.48% [Q4 2024] → 21.89% (+2.42%) [Q1 2025]
11% less funds holding
Funds holding: 28 [Q4 2024] → 25 (-3) [Q1 2025]
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
D. Boral Capital Jason Kolbert 22% 1-year accuracy 89 / 402 met price target | 1,063%upside $5 | Buy Maintained | 30 Apr 2025 |
HC Wainwright & Co. Yi Chen 34% 1-year accuracy 55 / 160 met price target | 482%upside $2.50 | Buy Reiterated | 11 Apr 2025 |
Financial journalist opinion
Based on 5 articles about VNRX published over the past 30 days









